Connect your AI

Ginkgo Bioworks DNA Restricted cash equivalents included in Other long-term assets

Restricted cash equivalents included in Other long-term assets at other companies

Vor BiopharmaVOR

$168K-93.0%

Slide Insurance Holdings, Inc. Common StockSLDE

$482.05M—

CorMedixCRMD

$332K—

Dyne Therapeutics, Inc.DYN

$15.59M+703%

Achieve Life SciencesACHV

$52K+33.3%

Liberty Broadband CorporationLBRDK

$46M+142%

Other financials

Income statement

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashEquivalentsNoncurrent.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's restricted cash equivalents included in other long-term assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ginkgo Bioworks's restricted cash equivalents included in other long-term assets?: Ginkgo Bioworks (DNA) reported restricted cash equivalents included in other long-term assets of $37.92M in Q1 2026.
How has Ginkgo Bioworks's restricted cash equivalents included in other long-term assets changed year-over-year?: Ginkgo Bioworks's restricted cash equivalents included in other long-term assets increased by 8.2% year-over-year, from $35.04M to $37.92M.